Ki67 protein: the immaculate deception?

被引：432
作者：
Brown, DC [1 ]
Gatter, KC
机构：
[1] Whittington Hosp, Dept Histopathol, London N19 5NF, England
[2] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England
来源：
HISTOPATHOLOGY | 2002年 / 40卷 / 01期
关键词：
Ki67; protein; characterization; function; prognosis; diagnosis;
D O I：
10.1046/j.1365-2559.2002.01343.x
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
This article updates our previous review of K167 published in Histopathology 10 years ago. In this period the numbers of papers published featuring this antibody has increased 10-fold from 338 to 3489 indicating the considerable enthusiasm with which this antibody has been studied. This review attempts to provide an update on the characterization of the Ki167 protein, its function and its use as a prognostic or diagnostic tool.
引用
收藏
页码：2 / 11
页数：10
相关论文
共 172 条
[1]   Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer [J].
Aaltomaa, S ;
Lipponen, P ;
Vesalainen, S ;
AlaOpas, M ;
Eskelinen, M ;
Syrjanen, K .
EUROPEAN UROLOGY, 1997, 32 (04) :410-415
[2]   Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53 [J].
Abdelsayed, RA ;
Guijarro-Rojas, M ;
Ibrahim, NA ;
Sangueza, OP .
JOURNAL OF CUTANEOUS PATHOLOGY, 2000, 27 (04) :169-175
[3]   Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy [J].
Ahlgren, G ;
Pedersen, K ;
Lundberg, S ;
Aus, G ;
Hugosson, J ;
Abrahamsson, PA .
UROLOGY, 1999, 54 (02) :329-334
[4]   EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].
ARCHER, SG ;
ELIOPOULOS, A ;
SPANDIDOS, D ;
BARNES, D ;
ELLIS, IO ;
BLAMEY, RW ;
NICHOLSON, RI ;
ROBERTSON, JFR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1259-1266
[5]   The impact of tumour angiogenesis, p53 overexpression and proliferative activity (MIB-1) on survival in squamous cervical carcinoma [J].
AvallLundqvist, EH ;
Silfversward, C ;
Aspenblad, U ;
Nilsson, BR ;
Auer, GU .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) :1799-1804
[6]  
Bai XZ, 1999, INT J ONCOL, V14, P785
[7]  
Baretton GB, 1996, CANCER, V77, P255, DOI 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO
[8]  
2-L
[9]   USEFULNESS OF IMMUNOHISTOCHEMICAL STAINING FOR P53 IN THE PROGNOSIS OF BREAST CARCINOMAS - CORRELATIONS WITH ESTABLISHED PROGNOSIS PARAMETERS AND WITH THE PROLIFERATION MARKER, MIB-1 [J].
BECK, T ;
WELLER, EE ;
WEIKEL, W ;
BRUMM, C ;
WILKENS, C ;
KNAPSTEIN, PG .
GYNECOLOGIC ONCOLOGY, 1995, 57 (01) :96-104
[10]   Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy [J].
Bettencourt, MC ;
Bauer, JJ ;
Sesterhenn, IA ;
Mostofi, FK ;
McLeod, DG ;
Moul, JW .
JOURNAL OF UROLOGY, 1996, 156 (03) :1064-1068
12345678910